How could Trevi Therapeutics' chronic cough drug development affect Merck?
New chronic cough drug may increase competition for Merck Trevi Therapeutics is advancing Haduvio, an oral nalbuphine extended-release formulation, through clinical trials for various chronic cough indications, including refractory chronic cough (RCC). If the company secures FDA approval, Haduvio would enter the market as a new treatment option. This successful entry creates direct competition for Merck in the chronic respiratory and cough treatment space, potentially impacting Merck's market share and revenue in those areas.
- Effect
- Mild negative
- How direct
- 2 steps, 1 inferred by Brind
- When
- Within months
- The story
- No new developments lately
How it reaches Merck
-
As of September 30, 2026, the company reported $299.4 million in cash and marketable securities, up from $188.3 million at the end of 2025. The company stated its current cash runway is sufficient to fund lead clinical programs through potential FDA approval. Research and Development Expenses increased to $19.1 million, primarily due to costs for the OCEAN-1, OCEAN-2, and LAKE clinical trials.
The full event1independent outlet -
Trevi Therapeutics is funding lead clinical programs for Haduvio, which is being evaluated for IPF, non-IPF-ILD, and RCC. The company is aligned with the FDA on the development pathway for non-IPF-ILD-related chronic cough, planning a Phase II dose-ranging study with approximately 120 patients.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- aol.com Tuesday
-
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Everything about company -
Should Trevi Therapeutics achieve FDA approval for Haduvio, it would introduce a new therapeutic option into the chronic cough market. This market is characterized by a high unmet medical need, and the company noted the absence of active competitive programs in the RCC space following recent clinical failures.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
public company in Indonesia
Everything about Merck
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The company's cash runway extends into 2030, sufficient to fund lead clinical programs through potential FDA approval.aol.com
- The non-IPF-ILD market opportunity more than doubles the IPF potential for Haduvio.aol.com
- The company is conducting the LAKE Phase IIb Trial SSRE for refractory chronic cough (RCC).aol.com
- The FDA has been collaborative and clear in discussions regarding the development plan for non-IPF-ILD chronic cough.aol.com
Why it matters
For Merck, the introduction of a successful, approved drug like Haduvio represents a direct competitive challenge in the chronic respiratory and cough treatment sector. As a major pharmaceutical player, Merck must monitor the success of this program to protect its market share and revenue streams in related indications.
The market for chronic cough is defined by a significant unmet medical need, with patients experiencing up to 1,500 coughs per day. While Trevi Therapeutics noted the absence of active competitive programs in the RCC space, the successful launch of Haduvio could quickly change the competitive dynamics, forcing established players like Merck to adjust their strategies or accelerate their own pipeline development.
What we don't know yet
- Will the LAKE Phase IIb Trial SSRE confirm trial powering for the RCC indication?
- How will the FDA respond to the Phase II dose-ranging study for non-IPF-ILD patients?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Center for Drug Evaluation and ResearchPossibleCDER's review workload increases as drug seeks approval for new chronic cough indications
- CongressPossibleFDA's support for new chronic cough drugs may influence future regulatory mandates
- Drug Enforcement AdministrationPossibleNew nalbuphine formulation may require DEA oversight for chronic cough
- Eli Lilly and CompanyPossibleNew chronic cough drug may increase competition for Eli Lilly
- United States of AmericaPossibleNew chronic cough drug approval could set new standards for US patient care.
Reporting
- aol.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.